First-in-kind kidney cancer drug developed at UTSW receives FDA approval

By | August 24, 2021
A first-in-kind kidney cancer drug developed from laboratory and translational studies conducted at UT Southwestern Medical Center received approval from the Food and Drug Administration, providing a new treatment for patients with familial kidney cancer.